Literature DB >> 33596668

SARS-CoV-2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID-19.

Peder L Myhre1,2, Christian Prebensen2,3, Christine Monceyron Jonassen4, Jan Erik Berdal2,3, Torbjørn Omland1,2.   

Abstract

Background COVID-19 may present with a variety of cardiovascular manifestations, and elevations of biomarkers reflecting myocardial injury and stress are prevalent. SARS-CoV-2 has been found in cardiac tissue, and myocardial dysfunction post-COVID-19 may occur. However, the association between SARS-CoV-2 RNA in plasma and cardiovascular biomarkers remains unknown. Methods and Results COVID MECH (COVID-19 Mechanisms) was a prospective, observational study enrolling consecutive, hospitalized patients with laboratory-confirmed infection with SARS-CoV-2 and symptoms of COVID-19. Biobank plasma samples used to measure SARS-CoV-2 RNA and cardiovascular and inflammatory biomarkers were collected in 123 patients at baseline, and in 96 patients (78%) at day 3. Patients were aged 60±15 (mean ± SD) years, 71 (58%) were men, 68 (55%) were White, and 31 (25%) received mechanical ventilation during hospitalization. SARS-CoV-2 RNA was detected in plasma from 48 (39%) patients at baseline. Patients with viremia were more frequently men, had more diabetes mellitus, and lower oxygen saturation. Patients with viremia had higher concentrations of interleukin-6, C-reactive protein, procalcitonin, and ferritin (all <0.001), but comparable levels of cTnT (cardiac troponin T; P=0.09), NT-proBNP (N-terminal pro-B-type natriuretic peptide; P=0.27) and D-dimer (P=0.67) to patients without viremia. SARS-CoV-2 RNA was present in plasma at either baseline or day 3 in 50 (52%) patients, and these patients experienced increase from baseline to day 3 in NT-proBNP and D-dimer concentrations, while there was no change in cTnT. Conclusions SARS-CoV-2 viremia was associated with increased concentrations of inflammatory, but not cardiovascular biomarkers. NT-proBNP and D-dimer, but not cTnT, increased from baseline to day 3 in patients with viremia. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04314232.

Entities:  

Keywords:  COVID‐19; RNA; SARS‐CoV‐2; biomarkers; cardiovascular; viremia

Year:  2021        PMID: 33596668     DOI: 10.1161/JAHA.120.019756

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  6 in total

1.  SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort.

Authors:  Emilia Roy-Vallejo; Laura Cardeñoso; Ana Triguero-Martínez; Marta Chicot Llano; Nelly Zurita; Elena Ávalos; Ana Barrios; Julia Hernando; Javier Ortiz; Sebastián C Rodríguez-García; Marianela Ciudad Sañudo; Celeste Marcos; Elena García Castillo; Leticia Fontán García-Rodrigo; Begoña González; Rosa Méndez; Isabel Iturrate; Ancor Sanz-García; Almudena Villa; Ana Sánchez-Azofra; Begoña Quicios; David Arribas; Jesús Álvarez Rodríguez; Pablo Patiño; Marina Trigueros; Miren Uriarte; Alexandra Martín-Ramírez; Cristina Arévalo Román; José María Galván-Román; Rosario García-Vicuña; Julio Ancochea; Cecilia Muñoz-Calleja; Elena Fernández-Ruiz; Rafael de la Cámara; Carmen Suárez Fernández; Isidoro González-Álvaro; Diego A Rodríguez-Serrano
Journal:  Front Med (Lausanne)       Date:  2022-06-15

Review 2.  Use and Prognostic Implications of Cardiac Troponin in COVID-19.

Authors:  Laura De Michieli; Allan S Jaffe; Yader Sandoval
Journal:  Cardiol Clin       Date:  2022-03-31       Impact factor: 2.410

3.  Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations.

Authors:  Louisa Helms; Silvia Marchiano; Ian B Stanaway; Tien-Ying Hsiang; Benjamin A Juliar; Shally Saini; Yan Ting Zhao; Akshita Khanna; Rajasree Menon; Fadhl Alakwaa; Carmen Mikacenic; Eric D Morrell; Mark M Wurfel; Matthias Kretzler; Jennifer L Harder; Charles E Murry; Jonathan Himmelfarb; Hannele Ruohola-Baker; Pavan K Bhatraju; Michael Gale; Benjamin S Freedman
Journal:  JCI Insight       Date:  2021-12-22

4.  Multiple Approaches at Admission Based on Lung Ultrasound and Biomarkers Improves Risk Identification in COVID-19 Patients.

Authors:  Jorge Rubio-Gracia; Marta Sánchez-Marteles; Vanesa Garcés-Horna; Luis Martínez-Lostao; Fernando Ruiz-Laiglesia; Silvia Crespo-Aznarez; Natacha Peña-Fresneda; Borja Gracia-Tello; Alberto Cebollada; Patricia Carrera-Lasfuentes; Juan Ignacio Pérez-Calvo; Ignacio Giménez-López
Journal:  J Clin Med       Date:  2021-11-23       Impact factor: 4.241

5.  High triglyceride to HDL-cholesterol ratio as a biochemical marker of severe outcomes in COVID-19 patients.

Authors:  Estefanía Alcántara-Alonso; Fernando Molinar-Ramos; Jesús Alberto González-López; Viridiana Alcántara-Alonso; Marco Antonio Muñoz-Pérez; José Juan Lozano-Nuevo; Daniel Rabindranath Benítez-Maldonado; Elizabeth Mendoza-Portillo
Journal:  Clin Nutr ESPEN       Date:  2021-05-07

6.  COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction.

Authors:  Kimberly A Queisser; Rebecca A Mellema; Elizabeth A Middleton; Irina Portier; Bhanu Kanth Manne; Frederik Denorme; Ellen J Beswick; Matthew T Rondina; Robert A Campbell; Aaron C Petrey
Journal:  JCI Insight       Date:  2021-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.